Compare VPG & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | LXRX |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.5M | 660.9M |
| IPO Year | 2010 | 2000 |
| Metric | VPG | LXRX |
|---|---|---|
| Price | $44.78 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $53.50 | $4.15 |
| AVG Volume (30 Days) | 209.6K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $307,202,000.00 | $49,803,000.00 |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $111.93 | ★ N/A |
| Revenue Growth | 0.22 | ★ 60.24 |
| 52 Week Low | $18.57 | $0.36 |
| 52 Week High | $56.25 | $1.83 |
| Indicator | VPG | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 50.40 |
| Support Level | $44.01 | $1.47 |
| Resistance Level | $48.61 | $1.65 |
| Average True Range (ATR) | 2.64 | 0.11 |
| MACD | 0.36 | -0.02 |
| Stochastic Oscillator | 67.19 | 35.71 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.